Biotech
AbCellera
AbCellera raises $555M Series B at $5.7B valuation
$555M
Total Raised
Series B
Latest Round
2012
Founded
400+
Employees
2389 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada
1 min read
Quick Facts
Valuation
$5.7B
Latest Round Size
$555M
Latest Round Date
June 2024
AbCellera: Series B Funding Round
AbCellera has successfully raised $555M in Series B funding, reaching a valuation of $5.7B.
Company Overview
Antibody discovery platform
Funding Details
The Series B round was led by Peter Thiel, with participation from Eli Lilly, Fast Forward Innovations, DCVC Bio.
Company Information
- Headquarters: 2389 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada
- Founded: 2012
- Employees: 400+
- Category: Biotech
Investment
AbCellera plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Peter Thiel: Verified investor in Series B
- Eli Lilly: Verified investor in Series B
- Fast Forward Innovations: Verified investor in Series B
- DCVC Bio: Verified investor in Series B
Key Investors
Peter Thiel
Lead Investor
Verified investor in Series B
Eli Lilly
Investor
Verified investor in Series B
Fast Forward Innovations
Investor
Verified investor in Series B
DCVC Bio
Investor
Verified investor in Series B
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Torl Biotherapeutics
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Editorial Team
Oct 10, 2025
1 min read•$96M
Biotech
Nilo Therapeutics
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Editorial Team
Oct 9, 2025
1 min read•$101M
Biotech
Arthrosi Therapeutics
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
Editorial Team
Oct 8, 2025
1 min read•$153M